First patent granted to Norwood Immunology
Tuesday, 17 February, 2004
Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology has been granted its first patent, covering the use of GnRH analogues to increase the T cell population for the treatment of a variety of diseases.
The patent, granted in South Africa, is the first of more than 100 patent applications filed in major jurisdictions around the world covering various aspects of the immunology project.
Director of marketing Bernie Romanin said that the granted patent provided recognition of the breadth of the application of the GnRH technology.
Norwood Immunology is in the process of listing on the London Stock Exchange's AIM market. Romanin said the listing process was progressing according to plan and the company expected it to list mid-year.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
